930 studies found for:    Open Studies | "Carcinoma, Bronchogenic"
Show Display Options
Rank Status Study
1 Recruiting SAS in Patients With Bronchial Carcinoma
Conditions: Sleep Apnea Syndrome;   Bronchial Carcinoma
Intervention: Device: sleep apnea screening with ApneaLinkTM
2 Recruiting Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics
Conditions: Tumors;   Carcinoma, Bronchogenic;   Breast Carcinoma;   Cancer of Head and Neck;   Lymphoma, Malignant;   Soft Tissue Neoplasms
Intervention: Drug: 18F-Al-NOTA-PRGD2 PET/CT
3 Unknown  Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy
Condition: Squamous Cell Carcinoma of Bronchus
Intervention: Drug: Gefitinib
4 Unknown  Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)
Condition: Recurrent Small Cell Lung Cancer
Intervention: Drug: Bendamustin/Ribomustin
5 Recruiting Comparison of Different Types of Surgery in Treating Patients With Early-stage Non-small Cell Lung Cancer
Conditions: Stage IA Non-small Cell Lung Cancer;   Adenocarcinoma of the Lung;   Squamous Cell Lung Cancer
Intervention:
6 Recruiting Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)
Conditions: Lung Cancer;   Non-small Cell Lung Cancer (NSCLC)
Interventions: Drug: Dasatinib - 1A;   Drug: Afatinib - 1A;   Drug: Dasatinib - 1B;   Drug: Afatinib - 1B
7 Recruiting Role of PET Scan in the Evaluation of Early Response to Maintenance Treatment in Advanced Non-small-cell Lung Cancer
Condition: Non-small Cell Lung Cancer
Intervention: Device: PET scan imaging
8 Recruiting Docetaxel + Plinabulin vs Docetaxel as 2nd-Line Chemo in Patients With Advanced NSCLC With >1 Large Lung Lesion
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Plinabulin (DP);   Drug: Docetaxel (D)
9 Not yet recruiting Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)
Condition: Non-small Cell Lung Cancer
Interventions: Biological: pembrolizumab;   Other: Placebo
10 Recruiting AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies
Conditions: Lung Cancer;   Targeted Therapy
Intervention: Drug: AZD9291
11 Not yet recruiting TORC1/2 Inhibitor INK128 and EGFR Inhibitor AZD9291 in Treating Patients With Advanced EGFR Mutation Positive Non-small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor
Conditions: Recurrent Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions: Drug: EGFR Inhibitor AZD9291;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: TORC1/2 Inhibitor INK128
12 Not yet recruiting Selumetinib and Nab-Paclitaxel (Albumin-stabilized Nanoparticle Formulation) as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
Conditions: Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation;   Other: Pharmacological Study;   Drug: Selumetinib
13 Not yet recruiting Echocardiography for RILI Prediction
Condition: NSCLC
Intervention:
14 Recruiting A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations
Condition: EGFR-TKI-naïve Patients With NSCLC Harboring EGFR Activating Mutations
Interventions: Drug: ASP8273 Capsules;   Drug: ASP8273 Capsules A
15 Recruiting SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma
Conditions: Small Cell Lung Cancer;   Large Cell Neuroendocrine Carcinoma
Intervention: Drug: SC-002
16 Recruiting G1T28 (CDK 4/6 Inhibitor) in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)
Condition: Small Cell Lung Cancer
Interventions: Drug: G1T28 + carboplatin/ etoposide;   Drug: Placebo + carboplatin/ etoposide
17 Recruiting Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Crizotinib
18 Not yet recruiting A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
Conditions: Acute Myeloid Leukemia;   Myelodysplastic Syndromes;   Glioblastoma Multiforme;   Melanoma;   Non-Small Cell Lung Cancer;   Ovarian Cancer;   Pancreatic Cancer;   Sarcoma;   Renal Cell Carcinoma
Intervention: Drug: DSP-7888 Dosing Emulsion
19 Not yet recruiting Cediranib Maleate and Olaparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Metastatic Pancreatic Adenocarcinoma;   Pancreatic Adenocarcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Recurrent Non-Small Cell Lung Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Small Cell Lung Carcinoma;   Stage III Pancreatic Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Small Cell Lung Carcinoma;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIB Small Cell Lung Carcinoma;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Small Cell Lung Carcinoma;   Stage IVA Pancreatic Cancer;   Stage IVB Pancreatic Cancer;   Triple-Negative Breast Carcinoma
Interventions: Other: 18F-Fluoromisonidazole;   Drug: Cediranib Maleate;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Procedure: Positron Emission Tomography
20 Not yet recruiting EGFR Inhibitor AZD9291 and Necitumumab in Treating Patients With EGFR-Positive Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor
Conditions: EGFR Activating Mutation;   Recurrent Non-Small Cell Lung Carcinoma;   Stage IV Non-Small Cell Lung Cancer
Interventions: Drug: EGFR Inhibitor AZD9291;   Other: Laboratory Biomarker Analysis;   Biological: Necitumumab;   Other: Pharmacological Study

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years